Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
+1.4%		$0.01
$0.00
▼
$0.02
$941K-1.32219,863 shs249,981 shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
OASM
Oasmia Pharmaceutical AB (publ)
$1.46
$0.94
▼
$5.70
$375K0.9698,414 shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-6.67%-6.67%-14.63%+6.06%-23.08%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-75.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
+1.4%		$0.01
$0.00
▼
$0.02
$941K-1.32219,863 shs249,981 shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
OASM
Oasmia Pharmaceutical AB (publ)
$1.46
$0.94
▼
$5.70
$375K0.9698,414 shsN/A
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-6.67%-6.67%-14.63%+6.06%-23.08%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-75.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.08N/AN/A($2.64) per share0.00
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
OASM
Oasmia Pharmaceutical AB (publ)
$220K0.00N/AN/A$0.63 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.13N/AN/AN/A-46.42%-91.97%-61.93%N/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A
OASM
Oasmia Pharmaceutical AB (publ)
-$18.95MN/AN/AN/AN/A-8,633.64%-43.94%-28.92%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59
OASM
Oasmia Pharmaceutical AB (publ)
N/A
0.80
0.73

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
OASM
Oasmia Pharmaceutical AB (publ)
0.11%

Insider Ownership

CompanyInsider Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.01%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
OASM
Oasmia Pharmaceutical AB (publ)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120132.53 million113.12 millionNot Optionable
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data
OASM
Oasmia Pharmaceutical AB (publ)
5774.97 millionN/ANot Optionable

Recent News About These Companies

Double Bond Pharmaceutical International AB (DBPHAb)
October 31, 2024  |  investing.comhttps://www.investing.com/equities/double-bond-pharmaceutical-intl-income-statement
Sector-Health Care & Pharmaceuticals
May 17, 2024  |  newsweek.comN
BOEUF Bonesupport Holding AB (publ)
April 30, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/BOEUF
Lipigon Pharmaceuticals AB LPGO
March 22, 2024  |  morningstar.comM
LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript
March 6, 2024  |  gurufocus.comhttps://www.gurufocus.com/news/2375052/lsk-biopartners-inc-oasmia-pharmaceutical-ab-publ--special-call-transcript
Oasmia Pharmaceutical AB (publ) - Special Call Transcript
March 6, 2024  |  gurufocus.comhttps://www.gurufocus.com/news/2375055/oasmia-pharmaceutical-ab-publ--special-call-transcript
Resurs Holding AB (publ) (RESURS.ST)
February 7, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RESURS.ST/
QuiaPEG Pharmaceuticals Holding AB QUIA
January 6, 2024  |  morningstar.comM
Newbury Pharmaceuticals AB (NEWBRY)
November 29, 2023  |  investing.comhttps://www.investing.com/equities/newbury-pharmaceuticals-ab
Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme
September 26, 2023  |  bestmediainfo.comB
Lipigon Pharmaceuticals AB (LPGO)
September 14, 2023  |  investing.comhttps://www.investing.com/equities/lipigon-pharmaceuticals-ab
Speqta publ AB (SPEQT)
August 25, 2023  |  investing.comhttps://www.investing.com/equities/203-web-group-publ-ab
PRXXF Paradox Interactive AB (publ)
August 25, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/PRXXF
Notice of annual general meeting in Alzinova AB (publ)
April 25, 2023  |  privataaffarer.seP
Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ)
April 21, 2023  |  privataaffarer.seP
Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2)
April 2, 2023  |  europapress.esE
OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M
February 26, 2023  |  seekingalpha.comhttps://seekingalpha.com/news/3940679-oxe-marine-ab-publ-non-gaap-eps-of-sek043-revenue-of-sek322m
US regulators clear way for more monkeypox vaccine shipments
July 14, 2022  |  starherald.comS
PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN)
March 24, 2022  |  avanza.seA
Oasmia expands R&D ability with planned laboratory upgrade
March 17, 2022  |  privataaffarer.seP

Media Sentiment Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 08/24/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0071 +0.00 (+1.43%)
As of 03:49 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas